Stocks for MannKind have plummeted under an announcement by the Danbury-based company this morning that Sanofi has terminated its license agreement to develop and sell the inhaled insulin treatment Afrezza.  Mannkind said in a news release that it's reviewing its strategic options for Afrezza as a result of the termination.  TheStreet.com reports that the company is short on cash, deeply in debt and has no established infrastructure to sell Afrezza.  The financial website says the most likely end game for MannKind is bankruptcy.